Top Banner
HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160- 183 JAMA 289:2560-2572, 2003
55

HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Dec 27, 2015

Download

Documents

Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

HYPERTENSIVE DRUG THERAPY

Goodman & Gilman, 11th ed., pp. 845-869

Katzung 9th ed., pp. 160-183

JAMA 289:2560-2572, 2003

Page 2: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Blood Pressure

• Normotension defined as < 120/80 and > 100/60

• Prehypertension defined as 120-140/80-90

•Hypertension defined as > 140/90

» i. stage 1 140-160/90-100

» ii. stage 2 > 160/100

Page 3: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Control of Blood Pressure BP = (SV)

(HR) (TPR)•Sympathetic Nervous System

– Raises Stroke volume via ß1 receptor activation

– Raises Heart Rate via ß1 receptor activation

– Raises Resistance via receptor activation

Page 4: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Control of Blood Pressure BP = (SV)

(HR) (TPR)•Renin-angiotensin system

– Vasopressor system with salt-retaining effects

– Raises resistance via Angiotensin (AT1) receptor activation

•Plasma volume - affects stroke volume

Page 5: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Sites of action of Antihypertensive

agents• Diuretics (Thiazides, Loop Diuretics, Potassium sparing)

• ß Blockers (Propranolol and other “olols”)

• Renin angiotensin disrupters (ACE inhibitors, angiotensin receptor blockers)

• Calcium channel blockers (Nifedipine etc.)

Page 6: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Sites of action of Antihypertensive agents (cont)

blockers (Terazosin and other “azosins”)

Arteriole-selective vasodilators (Hydralazine, Diazoxide, Minoxidil etc)

Norepinephrine depleting agents (Guanethidine, Reserpine, Guanadrel)

agonists ( methyl dopa, clonidine, others)

Page 7: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Sites of action of Antihypertensive agents (cont)

Ganglionic Blockers (nicotinic receptor antagonist-Trimethaphan)

Page 8: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Ach NE

Renin Converting Enzyme Kidney Angiotensinogen ‡ Angiotensin I ‡ Angiotensin II

ß1

1

Brain (2)

Heart

Vessel

N

AT1 1. Diuretics 3. Renin-

angiotensin inhibitors

4. Calcium Channel Blockers

5. blockers

6. Vasodilators

7. Norepinephrine depleting agents

2. ß blockers 8. 2 agonists

9. Ganglionic Blockers

Page 9: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Ideal anti-hypertensive agent

•Decreases systolic/diastolic pressure

•Does not alter cardiac output maintenance

•Does not cause orthostatic hypotension

•Does not produce major changes in regional blood flow

Page 10: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Ideal anti-hypertensive agent

•Is not subject to the development of tolerance

•Is easy to administer to facilitate patient compliance

•Has no limiting side effects or toxicity

• Thiazide diuretics, beta blockers, renin angiotensin system inhibitors and calcium channel antagonists are considered to be closest to ideal

Page 11: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Diuretics

• decrease Na+ and blood volume so pressure is more dependent on vascular resistance. Therefore, they potentiate the antihypertensive effects of other agents reducing TPR, particularly converting enzyme inhibitors or angiotensin receptor blockers.

Page 12: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Diuretics

• Thiazide diuretics • Loop diuretics• Potassium - sparing diuretics

Page 13: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Thiazide diuretics

• HYDROCHLOROTHIAZIDE (Microzide), Chlorothiazide (Diuril), Polythiazide (Renese), CHLORTHALIDONE (Chlorthalidone), indapamide (Lozol), Metalozone (Mykrox)

Page 14: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Thiazide diuretics

•Increase Na+ excretion and reduce plasma volume but these effects can be separated from the antihypertensive action

•Should usually be the first drugs used for hypertension therapy

•Decrease total peripheral resistance through vasodilator action on smooth muscle (activate a potassium channel to hyperpolarize smooth muscle)

Page 15: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Thiazide diuretics • Can cause hypokalemia, hyperglycemia (activate potassium channel in ß cells of pancreas to hyperpolarize & reduce insulin secretion) and hyperuricemia (gout)

• Considered to be excellent choices for the generic hypertensive and hypertension in African Americans and elderly- compelling indication for use in hypertension associated with: heart failure; diabetes, prevention against stroke

• Considered to be a poor choice in patients with gout or hyponatremia (no longer considered dangerous in diabetes mellitus even though they suppress insulin)

Page 16: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Loop diuretics

•FUROSEMIDE, ethacrynic acid, bumetanide - not used much in hypertension

•Decrease in BP correlates with loss in body weight

Page 17: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Potassium - sparing diuretics

•Spironolactone (Aldactone) and Eplerenone (Inspra) are aldosterone receptor antagonists

•TRIAMTERENE (Dyrenium) and Amiloride (Midamor) inhibit Na+ channels (ENaC) resulting in reduced K+ and H+ loss in the distal tubule of kidney

•Decrease potassium loss during diuretic therapy

Page 18: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Potassium - sparing diuretics

•Spironolactone & Eplerenone used to treat primary aldosteronism

•Can cause severe hyperkalemia

•Compelling use for Spironolactone or Eplerenone in hypertension associated with heart failure or post-myocardial infarction

Page 19: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers - Act to decrease cardiac output

•Non selective

•ß1 selective

•Partial agonists•Combined alpha & ß blockade

Page 20: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers

• Non selective

– PROPRANOLOL (Inderal), NADOLOL (Corguard), pindolol (Visken), penbutolol, (Levatol), bisoprolol (Zabeta)

– Produce negative inotropic and chronotropic effects and little orthostatic hypotension

– Disadvantages are reflex vasoconstriction, fluid retention and efficacy is dependent on adrenergic tone & can produce bronchospasm in asthmatics, hypoglycemia in diabetics and hypertension in pheochromocytoma

Page 21: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers

ß1 selective

– METOPROLOL (Lopressor), ATENOLOL (Tenormin), acebutolol, (Sectral), and betaxolol (Kerlone)

– Advantages and disadvantages are the same as those for non-selective beta antagonists except that ß1 antagonists are less likely to produce asthma, hypoglycemia in a diabetic or hypertension in pheochromocytoma

Page 22: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers

•Partial agonists (pindolol, acebutolol, penbutolol) are less likely to lower heart rate and they are vasodilators (called intrinsic sympathomimetic activity)

•Combined alpha & ß blockade- Labetalol (Normodyne, Trandate) and Carvedilol (Coreg)

Page 23: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers

– compelling indication for ß blocker use in treating hypertension associated with heart failure, angina pectoris, post-myocardial infarction, and diabetes mellitus. Good in hypertension associated with migraine headache, atrial tachycardia, hyperthyroidism or tremor

Page 24: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

ß adrenergic blockers

• ß blockers are poor choices in hypertension associated with asthma, depression, heart block; most recent guidelines do not include peripheral vascular disease or diabetes mellitus or hyperlipidemia

Page 25: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Renin dependent antihypertensives

• Converting Enzyme Inhibitors• Angiotensin receptor antagonists• Renin inhibitor • Less effective in African-Americans than diuretics or calcium channel antagonists

• Angiotensin receptor blocking agents and converting enzyme inhibitors are essentially equivalent

Page 26: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Converting Enzyme Inhibitors

• CAPTOPRIL (Capoten) , ENALAPRIL (Vasotec), LISINOPRIL (Prinivil, Zestrin) , fosinopril (Monopril) , ramipril (Altace), benazopril, (Lotensin), Perindopril (Aceon), quinapril (Accupril), moexepril, (Univsasc), trandolapril (Mavik)

• Decrease TPR• renal protective in patients with diabetes mellitus or chronic renal disease

• Disadvantages are cough, angioedema, nephropathies, leukopenia and agranulocytosis; teratogenic effects-avoid in pregnancy

Page 27: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Converting Enzyme Inhibitors

• diuretics markedly potentiate anti-hypertensive effects (Na & volume depletion makes blood pressure more dependent on renin-angiotensin system)

• less effective in African-Americans than diuretics or calcium channel blockers

• Compelling indication for treatment of hypertension associated with diabetes mellitus, chronic kidney disease, congestive heart failure or left ventricular dysfunction, post myocardial infarction and danger of stroke

Page 28: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Angiotensin receptor antagonists

•Losartan,(Cozaar), Valsartan (Diovan); Irbesartan (Avapro); Candesartan (Atacand); Telmisartan (Micardis); Eprosartan (Teveten), Irbesartan (Avapro), Olmesartan (Benicar))

•Apparently do not cause cough, as Captopril et al. do (don’t potentiate kinins)

Page 29: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Renin Inhibitor

•Aliskerin (Tekturna)– Blocks formation of angiotensin I by inhibiting renin

– Approved for use in 2007– Side effects are diarrhea, rash and hyperkalemia

– More expensive than other renin-angiotensin inhibitors

– Significance as an antihypertensive not established yet

Page 30: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Calcium Channel Blocking Agents

• inhibit voltage sensitive calcium channels (usually L channels) to reduce calcium entry into smooth muscle

Page 31: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Calcium Channel Blocking Agents (cont)

• VERAPAMIL (Calan, Isoptin etc); DILTIAZEM (Cardizem); Nicardipine (Cardene); NIFEDIPINE (Procardia, Adalat)- only extended release forms; short-acting forms are reported to increase mortality

• Others include amlodipine (Norvasc), felodipine (Plendil), Isradipine (Dynacirc), Nisoldipine (Sular)

• Actions are to vasodilate (reduce TPR)– 1. DILTIAZEM and VERAPAMIL contraindicated with ß blockers (they suppress cardiac contractions, as ß blockers do)

Page 32: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Calcium Channel Blocking Agents (cont)

•Considered to be a good choice in hypertensive African Americans and a compelling choice in hypertension associated with angina pectoris or diabetes mellitus

•A major side effect is edema

•T channel inhibitor- Mibefradil (Posicor)- blocks T channels to decrease resistance and blood pressure

Page 33: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Peripherally acting adrenergic antagonists

• PRAZOSIN (Minipress), doxazosin (Cardura) and TERAZOSIN (Hytrin)

• Act to dilate arterioles by blocking the constrictor effect of catecholamines

• Produce orthostatic and exertion related hypotension - block venoconstriction

• Act to decrease TPR blockers are considered good choices in hypertension associated with prostatic hypertrophy (they attenuate the

hypertrophy)

Page 34: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Direct acting vasodilators

•Arteriole - Specific•Arteriolar and Venodilators

Page 35: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Arteriole - Specific

Hydralazine (Apresoline)• Decreases TPR but doesn't produce much orthostatic hypotension (veins are not dilated)

• Disadvantage is reflex tachycardia and fluid retention

• Given orally, Metabolized by liver (highly variable)

• Side effects are palpitations, headache - usually prevented by ß blockade; also a lupus-like syndrome

• parenteral drug of choice for pregnancy-induced hypertension

Page 36: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Arteriole - Specific

Minoxidil (Loniten; Rogaine)– Similar to hydralazine in mechanism, use, and side effects but doesn't produce the lupus syndrome

– Hypertrichosis (hair growth) is a common side effect (used topically for hair growth)

– Usually reserved for severe, resistant hypertension

– Diazoxide (Hyperstat IV) Thiazide-like vasodilator not mentioned in JNC VII report (JAMA article)

Page 37: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Arteriolar and Venodilators

Nitroprusside (Nipride)

– Mechanism is to rapidly dilate both veins and arteries (elevates cGMP concentrations in smooth muscle by activating guanylyl cyclase)

– Blood pressure can be reduced to any level

– Only given i.v., short term treatment

– Used in surgical hypotension, hypertensive crisis, dissecting aneurysms, heart failure, ergot poisoning

Page 38: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Norepinephrine depleting agents

•Reserpine (Serpasil), guanethidine (Ismelin), guanadrel (Hylorel).

•Decrease total peripheral resistance and cardiac output with little reflex tachycardia

•Disadvantages are an initially elevated BP, bradycardia, postural hypotension, fluid retention, and efficacy dependent on sympathetic tone

•No compelling reason to use these agents

Page 39: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Centrally acting 2

agonists• methyldopa (Aldomet), clonidine (Catapress) guanabenz (Wytensin), guanfacine (Tenex)

• Mechanism of action is to inhibit sympathetic nerve activity via activation of 2 receptors- decrease both TPR and Cardiac Output

• methyl-dopa - Drug of choice in pregnancy-induced hypertension (the only compelling reason for its use)

• Advantages of these drugs include a decrease in TPR but negligible orthostatic hypotension

• Some disadvantages are fluid retention and efficacy is dependent on sympathetic tone [depression]

Page 40: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Ganglionic (nicotinic receptor) blockers • Mecamylamine (Inversine), Trimethaphan (Arfonad) and Hexamethonium

• Block autonomic ganglia, therefore decrease sympathetic tone on vessels

• Were used in hypertensive crises and to produce surgical hypotension but no compelling rationale for use (no longer manufactured in USA)

• Enormous number of side effects discourage the use of these drugs

Page 41: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Specific Treatment

• Essential hypertension (from JAMA 289: 2560-2572, 2003)

• Renal hypertension - cure is surgery or angioplasty but can be controlled with CAPTOPRIL, ENALAPRIL, etc. (these agents can cause renal failure in this condition)

• Pheochromocytoma - BP can be controlled with phentolamine or phenoxybenzamine ( blockers), surgical removal is cure

• Hypertensive crisis –treat with rapid acting vasodilator (nitroprusside, LABETALOL)

• Pregnancy-induced hypertension- -methyldopa (aldomet) is preferred agent; Hydralazine (Apresoline) is a good alternative and preferred parenteral agent

Page 42: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Essential hypertension

• If prehypertensive, treat with lifestyle modifications but not drugs unless they have diabetes meillitus or chronic kidney disease

• If stage I hypertensive (140-160/90-100), encourage lifestyle modification and initiate drug therapy, preferably a thiazide diuretic

• If stage II hypertension (>160/100), encourage lifestyle modifications but start drug therapy usually with 2 agents, including a thiazide diuretic in combination with a renin-angiotensin system disruptor (ACE inhibitor or angiotensin receptor blocker), ß blocker, or calcium channel blocker.

• If response still inadequate, add a second or third agent from a different class

Page 43: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.
Page 44: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Compelling reasons for antihypertensive use

• Thiazide diuretics- Congestive heart failure; diabetes mellitus; prevention of stroke

• Spironolactone/Eplerenone- Congestive heart failure; after a myocardial infarction

• Propranolol (ß blockers)- Congestive heart failure; Angina pectoris; after a myocardial infarction; diabetes mellitus

• Renin-angiotensin disrupters- Diabetes mellitus; Chronic kidney disease; Congestive heart failure; after myocardial infarction; prevention of stroke

• Calcium channel blockers (nifedipine etc)- Angina pectoris; Diabetes mellitus

Page 45: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.
Page 46: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Conditions precluding use of certain

antihypertensive agents

• Thiazide diuretics (Hydrochlorothiazide et al.)- hyponatremia; gout

• Propranolol (ß blockers)- Asthma; depression; heart block

Page 47: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

Hypertensive conditions in which a

certain antihypertensive is

good• Propranolol (ß blockers)- migraine headache; atrial tachycardia; hyperthyroidism; tremor

• Nifedipine (Calcium channel blockers)- African Americans

• Terazosin (Alpha 1 blockers)- prostatic hypertrophy

• Hydralazine- pregnancy-induced hypertension

• Alpha methyl DOPA- pregnancy-induced hypertension

Page 48: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A male 36 year old patient has a blood pressure of 144/96. He is training for a marathon. Which of the following is the best treatment for his hypertension:

• Enalapril • Hydrochlorothiazide• Nifedipine• Propranolol• Spironolactone

Page 49: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 35 year old male diabetic patient has a blood pressure of 140/90 with proteinuria. Which of the following would be the most

appropriate treatment:

a) Enalaprilb) Hydrochlorothiazidec) Hydralazined) Nifedipinee) Propranolol

Page 50: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 55 year old male patient has a blood pressure of 145/95 with chest pain upon

physical exertion. Which of the following would you give:

a) Enalaprilb) Hydrochlorothiazidec) Hydralazined) Nifedipinee) Propranolol

Page 51: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 55 year old male patient has a blood pressure of 150/98. He had a myocardial

infarction two weeks earlier. Which of the following would you give to treat his

hypertension:

a) Enalaprilb) Hydrochlorothiazidec) Hydralazined) Nifedipinee) Propranolol

Page 52: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 55 year old female patient has a blood pressure of 150/98. She has a history of migraine headaches. Which of the following would you give to treat her hypertension:

a) Enalaprilb) Hydrochlorothiazidec) Hydralazined) Nifedipinee) Propranolol

Page 53: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 63 year old male patient has a blood pressure of 145/95. He has been studying to be a pianist and complains about tremor while

performing. How would you treat his hypertension:

a) Enalaprilb) Hydrochlorothiazidec) Nifedipined) Propranolole) Spironolactone

Page 54: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 58 year old female patient has a blood pressure of 130/88 after treatment with one antihypertensive agent. She recently is suffering acute attacks of gout. Which of the following antihypertensive treatment is

most likely to be the cause:a) Enalaprilb) Hydrochlorothiazidec) Nifedipined) Propranolole) Spironolactone

Page 55: HYPERTENSIVE DRUG THERAPY Goodman & Gilman, 11th ed., pp. 845-869 Katzung 9th ed., pp. 160-183 JAMA 289:2560-2572, 2003.

A 48 year old female patient has a blood pressure of 128/93 after treatment with one antihypertensive agent. She is an asthmatic and is suffering from a dramatic increase in the frequency of asthmatic attacks. Which of the following antihypertensive treatment is

most likely to be the cause:a) Enalaprilb) Hydrochlorothiazidec) Nifedipined) Propranolole) Spironolactone